Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 18;13(7):1087-1091.
doi: 10.18240/ijo.2020.07.11. eCollection 2020.

Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

Yi Qu  1 , Xin-Shu Liu  2 , An-Yi Liang  1 , Jun-Yan Xiao  1 , Chan Zhao  1   3 , Fei Gao  1 , Mei-Fen Zhang  1   3
Affiliations

Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

Yi Qu et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the efficacy and safety of subconjunctival triamcinolone acetonide (TA) injections for treating uveitic macular edema (UME).

Methods: This retrospective case series study included patients with UME who received subconjunctival TA injections with a minimum follow-up period of 6mo. The main outcome measure was central macular thickness (CMT). The secondary outcome measures included best-corrected visual acuity (BCVA), recurrence rate and intraocular pressure (IOP).

Results: In total, 65 patients (80 eyes), mainly including idiopathic uveitis in 33 patients (50.77%) and Vogt-Koyanagi-Harada (VKH) syndrome in 19 patients (29.23%), were enrolled in this study. The mean CMT decreased from 457.6±173.0 µm at baseline to 325.9±176.8, 302.7±148.2, 332.2±177.3 and 270.6±121.6 µm at 1-, 2-, 3- and 6-months postinjection, respectively (all P<0.001). BCVA increased from logMAR 0.5±0.3 at baseline to logMAR 0.4±0.3, 0.4±0.3, 0.4±0.4 and 0.4±0.3 at the 1-, 2-, 3- and 6-months postinjection visits, respectively (all P<0.001). Twenty-one (21/80, 26.25%) eyes underwent relapse of UME within 6mo. A total of 20/80 (25%) eyes exhibited elevated IOPs, of which 13 eyes were controlled with topical IOP-lowering agents and 7 eyes underwent surgical removal of subconjunctival TA deposit.

Conclusion: Subconjunctival TA injections appear to be safe and effective for UME.

Keywords: intraocular pressure; macular edema; subconjunctival injection; triamcinolone acetonide; uveitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1. CMT changes after the treatment with subconjunctival injection of TA
aP<0.001.
Figure 2
Figure 2. Mean visual acuity at baseline and the changes over time
aP<0.001.
See this image and copyright information in PMC

References

    1. Accorinti M, Okada AA, Smith JR, Gilardi M. Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm. 2019;27(2):169–180. - PubMed
    1. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11(1):29–38. - PubMed
    1. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–1449. - PubMed
    1. Multicenter Uveitis Steroid Treatment Trial Research Group. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550–561.e10. - PMC - PubMed
    1. Symes RJ, Forooghian F. Topical difluprednate monotherapy for uveitic macular edema. Can J Ophthalmol. 2016;51(1):47–49. - PubMed

LinkOut - more resources